However, T3D-959 treatment, an orally active brain-penetrating PPARδ/γ dual nuclear receptor agonist and a potent insulin sensitizer, ameliorated cognitive deficits and AD pathological hallmarks via promoted expression of insulin/IGF-1/Akt signaling proteins in the temporal lobes (de la Monte et al., 2017). The gene discussed is AKT1; the disease is Cognitive impairment.